Affiliation:
1. Dermatology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain
Abstract
Cutaneous cancers are, by far, the most common malignant neoplasms of the human being. Due to the great array of clinical conditions, their worldwide increasing incidence and the steady ageing of the population, non-invasive treatments modalities that show a good clinical response, a proper benefit–risk ratio and cosmetic results are becoming increasingly important in the clinical setting. Imiquimod is a topically applied immunomodulator which is often used in the management of several premalignant and malignant cutaneous disorders. This article is a review of the current literature on its mechanism of action, pharmacokinetics, and therapeutical effects.
Funder
Instituto de Salud Carlos III MINECO and Peder Funds
Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference84 articles.
1. Imiquimod for the Treatment of Skin Cancer;Burns;Dermatol. Clin.,2005
2. Nonsurgical Treatments for Nonmelanoma Skin Cancer;Collins;Dermatol. Clin.,2019
3. Interventions for Basal Cell Carcinoma of the Skin;Thomson;Cochrane Database Syst. Rev.,2020
4. Immunotherapy in Nonmelanoma Skin Cancer;Immunotherapy,2012
5. Role of Imiquimod in Skin Cancer Treatment;Urosevic;Am. J. Clin. Dermatol.,2004
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献